Overview

To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours
Phase:
Early Phase 1
Details
Lead Sponsor:
Sutphin Drugs
Collaborator:
Bharath Charitable Cancer Hospital and Institute
Treatments:
Doxorubicin
Liposomal doxorubicin